ASCO GU 2017: Best of Journals: Renal Cell Carcinoma – Urologic Oncology - Session Highlights

Orlando, Florida USA (UroToday.com) In this session, Dr. Uzzo reviewed the important surgical literature in renal cell carcinoma (RCC) from 2016. A systematic review of the Agency for Healthcare and Research Quality demonstrated that renal mass biopsy (RMB) is a safe and important tool. Twenty studies comprising 2,797 patients and 3,113 RMBs were included in the meta-analysis. The non-diagnostic rate was 14% and repeat biopsies in these cases were diagnostic in 80%. The false positive rate was only 4%. Core biopsy sensitivity and specificity were 97.5% and 96.2% respectively. Accuracy regarding grade concordance varied from 56-76% and upgrading from low to high grade occurred in 16%. Adverse events occurred in 5-7% of patients with hematoma (4.9%) being the most common. One area of controversy in RMB is an oncocytic diagnosis. Fortunately, annual growth rates for oncocytic lesions are 0.2-0.4 cm/year. In one study, eight patients (total n = 95) elected surgery over a period of 24 months’ median follow-up and no patients died of RCC.

ASCO GU 2017: Best of journals: Renal Cell Carcinoma - Radiologist - Session Highlights

Orlando, Florida USA (UroToday.com) Several important and innovative papers that were published in 2016, were reviewed.

ASCO GU 2017: Quality of care in non-muscle invasive bladder cancer: optimizing surgical and medical therapies - Session Highlights

Orlando, Florida USA (UroToday.com) Karim Chamie, UCLA, discussed the quality care for non-muscle invasive bladder cancer. There is a significant health burden associated with bladder cancer care.

ASCO GU 2017: Intravesical rAD-IFNa/Syn3 for patients with high-grade, Bacillus Calmette-Guerin (BCG) refractory or relapsed non-muscle invasive bladder cancer: a phase II randomized study - Session Highlights

Orlando, Florida USA (UroToday.com) Stephen Boorjian, Mayo clinic, discussed the results of the above trial. The trial was funded by FDK Therapies and conducted exclusively through the SUO-CTC.

ASCO GU 2017: Options for the Patient Who Does Not Respond to Bacillus Calmette-Guérin When Radical Cystectomy Is Not an Option - Session Highlights

Orlando, Florida USA (UroToday.com) James McKiernan, Columbia University, discussed options for the patient who does not respond to Bacillus Calmette-Guerin when radical cystectomy is not an option.

ASCO GU 2017: Barriers in Progress in Muscle-Invasive and Non-muscle Invasive Bladder Cancer - Oncology Perspective - Session Highlights

Orlando, Florida USA (UroToday.com) Noah Hahn, John Hopkins University, presented the oncology perspective on trial design in non-muscle invasive bladder cancer.

ASCO GU 2017: Barriers in Progress in Muscle-Invasive and Non-muscle Invasive Bladder Cancer - Urology Perspective - Session Highlights

Orlando, Florida USA (UroToday.com) Ashish Kamat, MD Anderson, discussed perspectives on trial design in non-muscle invasive bladder cancer. There are several myths when it comes to bladder cancer. Pathology is heterogeneous and disagreement among pathologists despite continued refinements in disease classification.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe